| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA5170263
Max Phase: Preclinical
Molecular Formula: C19H17N3O
Molecular Weight: 303.37
Associated Items:
Representations
Canonical SMILES: O=C1NCCc2c1cc(-c1ccncc1)n2Cc1ccccc1
Standard InChI: InChI=1S/C19H17N3O/c23-19-16-12-18(15-6-9-20-10-7-15)22(17(16)8-11-21-19)13-14-4-2-1-3-5-14/h1-7,9-10,12H,8,11,13H2,(H,21,23)
Standard InChI Key: SRUDZBMASYXMNS-UHFFFAOYSA-N
Associated Targets(Human)
Protein kinase N2 1991 Activities
Protein kinase N1 787 Activities
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 303.37 | Molecular Weight (Monoisotopic): 303.1372 | AlogP: 2.88 | #Rotatable Bonds: 3 |
| Polar Surface Area: 46.92 | Molecular Species: NEUTRAL | HBA: 3 | HBD: 1 |
| #RO5 Violations: 0 | HBA (Lipinski): 4 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 0 |
| CX Acidic pKa: | CX Basic pKa: 5.05 | CX LogP: 2.16 | CX LogD: 2.15 |
| Aromatic Rings: 3 | Heavy Atoms: 23 | QED Weighted: 0.81 | Np Likeness Score: -0.60 |
References
| 1. Scott F, Fala AM, Takarada JE, Ficu MP, Pennicott LE, Reuillon TD, Couñago RM, Massirer KB, Elkins JM, Ward SE.. (2022) Development of dihydropyrrolopyridinone-based PKN2/PRK2 chemical tools to enable drug discovery., 60 [PMID:35104640] [10.1016/j.bmcl.2022.128588] |
Source
Source(1):